Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2013

01-11-2013 | Brief Research Article

Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens

Authors: E. E. Habib, E. S. Fahmy

Published in: Clinical and Translational Oncology | Issue 11/2013

Login to get access

Abstract

Purpose

The aim of this prospective, phase II clinical study is to evaluate the activity of gemcitabine and cisplatin in comparison to pemetrexed and carboplatin in patients with malignant pleural mesothelioma.

Patients and methods

The patients were recruited from May 2008 to May 2011. One group included 21 cases who received cisplatin and gemcitabine. The other group included 19 cases who received pemetrexed and carboplatin.

Results

Response is superior in the pemetrexed group (p = 0.041). The median follow-up was 18 months (range 6–30 months). Cumulative survival at 1.5 years was 57.8 % for the pemetrexed carboplatin group. For the gemcitabine cisplatin group, the cumulative survival proportion at 1.5 years was 41 % (p = 0.0599).

Conclusions

Pemetrexed plus carboplatin are a step forward in the treatment of mesothelioma, the prognosis for these patients remains poor. Cheaper combinations as gemcitabine and cisplatin may be considered sufficient to treat cases with advanced mesothelioma.
Literature
1.
Wojtukiewicz MZ, Zacharski LR, Memoli VA et al (1989) Absence of components of coagulation and fibrinolysis pathways in situ in mesothelioma. Thromb Res 55:279–284PubMedCrossRef
2.
Sugarbaker DJ, Jaklitsch MT, Bueno R et al (2004) Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128:138–146PubMedCrossRef
3.
Baldini EH (2004) External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin 14:543–548PubMedCrossRef
4.
5.
Berghmans T, Paesmans M, Lalami Y et al (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38:111–121PubMedCrossRef
6.
Raghavan D, Gianoutsos P, Bishop J et al (1990) Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8:151–154PubMed
7.
Vogelzang NJ, Goutsou M, Corson JM et al (1990) Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukaemia Group B. Cancer Chemother Pharmacol 27:239–242PubMedCrossRef
8.
Hazarika M, White RM, Booth BP et al (2005) Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11:982–992PubMed
9.
Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644PubMedCrossRef
10.
Ong ST, Vogelzang NJ (1996) Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 14:1007–1017PubMed
11.
Zidar BL, Green S, Pierce HI et al (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a southwest oncology group study. Invest New Drugs 6:223–226PubMedCrossRef
12.
Millard FE, Herndon J, Vogelzang MR et al (1997) Gemcitabine for malignant mesothelioma: a phase II study of the cancer and leukemia group B (CALGB 9530). ProcAm Soc Clin Oncol 16:1710
13.
Bischoff HG, Manegold C, Knopp M et al (1998) Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17:1784
14.
Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 108:1122–1128PubMedCrossRef
15.
16.
Rusch VW (2003) Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol 21:2629–2630PubMedCrossRef
17.
Hughes A, Calvert P, Azzabi A et al (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20:3533–3544PubMedCrossRef
18.
Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A (2006) Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24:1443–1448PubMedCrossRef
19.
Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257–260PubMedCrossRef
20.
Fennell D, Steele J, Sheaff M et al (2005) Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer 49:S220
Metadata
Title
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens
Authors
E. E. Habib
E. S. Fahmy
Publication date
01-11-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1015-3

Other articles of this Issue 11/2013

Clinical and Translational Oncology 11/2013 Go to the issue

Research Article

Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma

Research Article

Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?

EDUCATIONAL SERIES–RED SERIES

Zoledronic acid in genitourinary cancer

Research Article

Early volumetric change and treatment outcome of metastatic brain tumors after external beam radiotherapy: differential radiotherapy for brain metastasis

Brief Research Article

Assessment of p38α in peripheral blood mononuclear cells (PBMC): a potential blood protein marker of head and neck squamous cell carcinoma

Special Article

New sequencing technologies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits